CLINICAL_TRIALS
trial_result
· 2021-09-28
Clinical Trial Update: RAD001 for Patients With Radioiodine Refractory Thyroid Cancer [Phase 2]
Summary
Phase 2 clinical trial update for RAD001 in patients with radioiodine refractory thyroid cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-28